Agalactosyl IgG is elevated in patients with active spondyloarthropathy

Rheumatology International

Volumn 18, Issue 5-6, 1999, Pages 171-176

  Leirisalo Repo, M ^a   Hernandez Munoz, H E ^b   Rook, G A W ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Agalactosylated IgG; Ankylosing spondylitis; Reactive arthritis; Spondyloarthropathy

Indexed keywords

GALACTOSE; IMMUNOGLOBULIN G;

ADULT; ARTICLE; CLINICAL ARTICLE; COLONOSCOPY; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; ENTERITIS; FEMALE; FOLLOW UP; GLYCOSYLATION; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; REACTIVE ARTHRITIS; SACROILIITIS; SPONDYLOARTHROPATHY;

EID: 0032980164     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002960050080     Document Type: Article

References (35)

1. 1. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K, Takeuchi F, Nagano Y, Miyamoto T, Kobata A (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316:452-457
2. 2. Dubé R, Rook GAW, Steele J, Brealey R, Dwek R, Rademacher T, Lennard-Jones J (1990) Agalactosyl IgG in inflammatory bowel disease: correlation with C-reactive protein. Gut 31:431-434
3. 3. Parekh R, Isenberg D, Rook G, Roitt I, Dwek R, Rademacher T (1989) A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun 2:101-114
4. 4. Parekh RB, Roitt IM, Isenberg DA, Dwek RA, Ansell BM, Rademacher TW (1988) Galactosylation of IgG associated oligosaccharides: reduction in patients with adult and juvenile onset rheumatoid arthritis and relation to disease activity. Lancet 1: 966-969
5. 5. Zeben D van, Hazes JMW, Zwinderman AH, Vandenbroucke JP, Breedveld FC (1993) Factors predicting outcome of rheumatoid arthritis: results of a follow-up study. J Rheumatol 20:1288-1296
6. 6. Zeben D van, Rook GAW, Hazes JMW, Zwinderman AH, Zhang Y, Ghelani S, Rademacher TW, Breedveld FC (1994) Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: results of a follow-up study. Br J Rheumatol 33:36-43
7. 7. Bodman-Smith K, Sumar N, Sinclair H, Roitt I, Isenberg D, Young A (1996) Agalactosyl IgG [Gal(0)] - an analysis of its clinical utility in the long-term follow-up of patients with rheumatoid arthritis. Br J Rheumatol 35:1063-1066
8. 8. Axford JS, Lydyard PM, Isenberg DA, Mackenzie L, Hay FC, Roitt IM (1987) Reduced B cell galactosyltransferase activity in rheumatoid arthritis. Lancet 2:1486-1488
9. 9. Bodman KB, Sumar N, Mackenzie LE, Isenberg DA, Hay FC, Roitt IM, Lydyard PM (1992) Lymphocytes from patients with rheumatoid arthritis produce agalactosylated IgG in vitro. Clin Exp Immunol 88:420-423
10. 10. Parekh R, Isenberg D, Roitt I, Dwek R, Rademacher T (1988) Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med 167:1731-1736
11. 11. Rademacher TW, Jones RHV, Williams PJ (1995) Significance and molecular basis for IgG glycosylation changes in rheumatoid arthritis. Adv Exp Med Biol 376:193-204
12. 12. Bond A, Sumar N, Bodman K, Colaco CB, Young A, Hay FC (1994) Relationship of IgG glycosylation, soluble IL-2 receptors and IL-6 to disease activity in rheumatoid arthritis. Br J Rheumatol 33:992-993
13. 13. Adler Y, Lamour A, Jamin C, Menez JF, Le Corre R, Shoenfeld Y, Youinou P (1995) Impaired binding capacity of asialyl and agalactosyl IgG to Fc gamma receptors. Clin Exp Rheumatol 13:315-319
14. 14. Axford JS (1991) Oligosaccharides: an optional extra or of relevance to disease mechanisms in rheumatology? J Rheumatol 18:1124-1127
15. 15. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB (1995) Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1:237-243
16. 16. Lahesmaa-Rantala R, Granfors K, Toivanen A (1986) Detection of circulating Yersinia-immunoglobulin complexes by enzyme immunoassay (EIA). J Immunol Methods 89:191-199
17. 17. Sieper J, Braun J (1995) Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum 38:1547-1554
18. 18. Märker-Hermann E, Höhler T (1998) Pathogenesis of human leukocyte antigen B27-positive arthritis: information from clinical materials. Rheum Dis Clin North Am 24:865-881
19. 19. Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M (1991) Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 18:1542-1551
20. 20. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppälä K (1994) High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 37:23-31
21. 21. Lauhio A, Leirisalo-Repo M, Lähdevirta J, Saikku P, Repo H (1991) Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 34:6-14
22. 22. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Olivieri I, Pasero G, Veys E, Zeidler H, the European Spondylarthropathy Study Group (1991) The European Spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218-1227
23. 23. Moll JMH, Wright V (1973) New York clinical criteria for ankylosing spondylitis. Ann Rheum Dis 32:354-363
24. 24. Wang Y, Rook GAW (1996) Analytical methods 3: monoclonal antibodies. In: Isenberg D, Rademacher TW (eds) Abnormalities of IgG glycosylation and immunological disorders. Wiley, Chichester, pp 89-99
25. 25. Williams PJ (1996) Analytical methods 1: biochemical. In: Isenberg D, Rademacher TW (eds) Abnormalities of IgG glycosylation and immunological disorders. Wiley, Chichester, pp 45-64
26. 26. Tomana M, Schrohenloher RE, Koopman WJ, Alarcón GS, Paul WA (1988) Abnormal glycosylation of serum IgG from patients with chronic inflammatory diseases. Arthritis Rheum 31:333-338
27. 27. Leirisalo-Repo M, Repo H (1992) Gut and spondyloarthropathies. Rheum Dis Clin North Am 18:23-35
28. 28. Rademacher TW, Jaques A, Williams PJ (1996) The defining characteristics of immunoglobulin glycosylation. In: Isenberg D, Rademacher TW (eds) Abnormalities of IgG glycosylation and immunological disorders. Wiley, Chichester, pp 1-44
29. 29. Hernández-Pando R, Reyes P, Espitia C, Wang Y, Rook G, Mancilia R (1994) Raised agalactosyl IgG and antimycobacterial humoral immunity in Takayasu's arteritis. J Rheumatol 21:1870-1876
30. 30. Young A, Sumar N, Bodman K, Goyal K, Sinclair H, Roitt I, Isenberg D (1991) Agalactosyl IgG: an aid to differential diagnosis in early synovitis. Arthritis Rheum 34:1425-1429
31. 31. Lastra GC, Thompson SJ, Lemonidis AS, Elson CJ (1998) Changes in the galactose content of IgG during humoral immune responses. Autoimmunity 28:25-30
32. 32. Rademacher TW, Williams P, Dwek RA (1994) Agalactosyl glycoforms of IgG autoantibodies are pathogenic. Proc Natl Acad Sci USA 91:6123-6127
33. 33. Pilkington C, Taylor PV, Silverman E, Isenberg DA, Costello AM de L, Rook GWA (1996) Agalactosyl IgG and materno-fetal transmission of autoimmune neonatal lupus. Rheumatol Int 16:89-94
34. 34. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B, Bertouch J, Brooks P, Edmonds J, Major G, Amor B, Calin A (1995) Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618-627
35. 35. Axford JS, Sumar N, Alavi A, Isenberg DA, Young A, Bodman KB, Roitt IM (1992) Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest 89:1021-1031